低分子肝素治疗重症肺心病呼吸衰竭的临床分析

Clinical Analysis of Low Molecular Weight Heparin in the Treatment of Respiratory Failure in Severe Pulmonary Heart Disease

目的:探讨低分子肝素治疗重症肺心病呼吸衰竭的临床价值。方法:选取近两年我院收治的62例重症肺心病呼吸衰竭患者作为研究对象,随机分为观察组(32)与参考组(30例),两组均接受改善通气、抗感染、换气等常规治疗,观察组同期接受低分子肝素治疗,观察两组治疗效果。结果:观察组治疗总有效率显著大于参考组(P<0.05);治疗前,两组pH、动脉血氧分压(PaO2)及动脉二氧化碳分压(PaCO2)等指标比较无统计学意义(P>0.05);治疗后,观察组各指标均显著优于参考组(P<0.05);观察组6min步行试验(6MWT)显著大于参考组(P<0.05);两组均未见不良反应。结论:低分子肝素治疗重症肺心病呼吸衰竭效果确切,可有效改善患者血气指标。

Objective:To investigate the clinical value of low molecular weight heparin(LMWH)in the treatment of respiratory failure in patients with severe cor pulmonale.Methods:62 patients with severe pulmonary heart disease and respiratory failure admitted to our hospital in recent two years were selected as the research object.They were divided into observation group(32)and reference group(30).Both groups received routine treatment such as improved ventilation,anti-infection and ventilation.The observation group received low molecular weight heparin treatment at the same time,and the therapeutic effect of the two groups was observed.Results:The total effective rate of the observation group was significantly higher than that of the reference group(P<0.05);before treatment,there was no significant difference in pH,PaO2 and PaCO2 between the two groups(P>0.05);after treatment,the indexes of the observation group were significantly better than those of the reference group(P<0.05);the 6-minute walking test(6MWT)of the observation group was significantly greater than that of the reference group(P<0.05).There were no adverse reactions in both groups.Conclusion:Low molecular weight heparin is effective in the treatment of respiratory failure in patients with severe cor pulmonale and can effectively improve the blood gas index.